Literature DB >> 21467632

Natural killer group 2A (NKG2A) and natural killer group 2C (NKG2C) bind to sulfated glycans and α2,3-NeuAc-containing glycoproteins.

Xin Xin1, Koji Higai, Yuzo Imaizumi, Chiho Suzuki, Kenichiro Ito, Ayumi Itoh, Sayo Matsumoto, Yutaro Azuma, Kojiro Matsumoto.   

Abstract

Killer lectin-like receptors on natural killer (NK) cells mediate cytotoxicity through glycans on target cells. We prepared recombinant glutathione S-transferase-fused extracellular lectin-like domains (AA 94-231) of natural killer group 2A (NKG2A) (rGST-NKG2A) and NKG2C (rGST-NKG2C) and determined the binding of these receptors to plates coated with heparin-conjugated bovine serum albumin (heparin-BSA) and glycoproteins. rGST-NKG2A and rGST-NKG2C directly bound to heparin-BSA with K(d) values of 20 and 40 nM, respectively. Binding of rGST-NKG2A and rGST-NKG2C to heparin-BSA was suppressed in the presence of soluble heparin, heparan sulfate, fucoidan, λ-carrageenan, and dextran sulfate. 2-O-Sulfate residues in heparin were essential for the binding of rGST-NKG2A and rGST-NKG2C. Moreover, rGST-NKG2A and rGST-NKG2C bound to multimeric sialyl Lewis X expressing transferrin secreted by HepG2 cells with K(d) values of 80 and 114 nM, respectively. This is the first report showing that NKG2A and NKG2C bind to heparin and α2,3-NeuAc-containing glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467632     DOI: 10.1248/bpb.34.480

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Fibulin-3, -4, and -5 are highly susceptible to proteolysis, interact with cells and heparin, and form multimers.

Authors:  Jelena Djokic; Christine Fagotto-Kaufmann; Rainer Bartels; Valentin Nelea; Dieter P Reinhardt
Journal:  J Biol Chem       Date:  2013-06-19       Impact factor: 5.157

Review 2.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.